You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)就漢斯狀商業化與Intas訂立許可協議
阿思達克 10-27 17:12
復宏漢霖(02696.HK)公布,與印度製藥公司Intas訂立一份許可協議,據此,公司同意向Intas授出獨家許可,供其於領域內及於約定的歐洲地區和印度商業化漢斯狀(斯魯利單抗注射液)。 公司將授予Intas於區域內及領域內商業化許可產品以及為該等商業化目的而使用相關知識產權和專有技術的獨家許可權及分許可權;根據許可協議及雙方後續另行簽訂的生產及供貨協議所約定的適用條件,生產許可產品的非獨家許可權及分許可權;及於許可協議適用條件下開發和商業化許可產品特定劑型的許可權。 Intas將向公司支付首付款合計至多4,200萬歐元、監管里程碑款項合計至多4,300萬歐元、商業銷售里程碑款項合計至多1億歐元、及以許可產品於區域內實現的年度淨利潤15%至27%不等的比例計算的特許權使用費。就Intas開發的特定劑型,Intas應向公司按年度淨銷售額5%支付特許權使用費。 集團指,本次與Intas就斯魯利單抗注射液於歐洲和印度的商業化合作將有助於進一步拓展公司產品的海外市場,增強產品在國際市場的可及性和認可度,從而為公司收入的持續提升創造條件。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account